Moderna slides as flu-vaccine regulatory overhang and risk-off trading weigh on shares
MRNA•Moderna shares fell about 3% Tuesday as investors continued to discount near-term revenue catalysts after recent flu-program headlines and a broader risk-off tape. The stock has also been pressured by lingering regulatory uncertainty around its seasonal flu shot mRNA-1010 after earlier FDA filing setbacks, keeping sentiment fragile.
1. What’s moving the stock
Moderna (MRNA) is down about 3% in Tuesday trading, extending a choppy stretch where the market has struggled to assign a clear near-term earnings catalyst to the company’s respiratory portfolio. Even with ongoing progress across flu and pandemic-influenza programs, the stock remains sensitive to sentiment shifts and incremental headlines that don’t immediately translate into 2026 revenue visibility. (investing.com)




